Ultragenyx Pharmaceutical Inc.
RARE
Market Cap$3.57B
Close$
$55.30
24.9% upside
Current Fair Value
24.9% upsideUndervalued by 24.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.57 Billion |
|---|---|
| Enterprise Value | $2.99 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-8.25 |
| Beta | 1.24 |
| Outstanding Shares | 82,300,000 |
| Avg 30 Day Volume | 693,667 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -5.89 |
|---|---|
| PEG | 31.2 |
| Price to Sales | 8.86 |
| Price to Book Ratio | 14.76 |
| Enterprise Value to Revenue | 6.89 |
| Enterprise Value to EBIT | -5.26 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
ESG Score
No data
About Ultragenyx Pharmaceutical Inc.
CEO: Emil Kakkis